News & Updates

Subcutaneous injection of risperidone QM or Q2M (TV-46000) has been shown to significantly delay impending relapse in patients with schizophrenia in the phase III RISE study.

Sexual dysfunction is highly prevalent in schizophrenia, affecting >50 percent of patients. Treatment of comorbid depression may be an effective strategy to improve sexual health, according to a meta-analysis.

A double-blind, placebo-controlled, randomized clinical trial reports significant improvement in agitation with brexpiprazole vs placebo among patients with Alzheimer’s dementia.

Depression levels among adults appear to be positively associated with respiratory symptoms, asthma, and chronic obstructive pulmonary disease (COPD), according to a study.

Patients with nonalcoholic fatty liver disease (NAFLD) tend to have higher rates of irritable bowel syndrome (IBS) symptoms, depression, and anxiety, suggests a study.

In patients with treatment-resistant depression, esketamine nasal spray appears to have superior efficacy compared with extended-release quetiapine when used in combination with conventional antidepressants.

Adults with attention-deficit/hyperactivity disorder (ADHD) face a nearly threefold higher risk of dementia compared with those who do not have the neurodevelopmental condition, according to a study.

Women of reproductive age with axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), or rheumatoid arthritis (RA) are more likely to experience postpartum depression than those without any rheumatic disease (RD), according to a study.

Gradual antipsychotic dose reduction does not provide benefits in social functioning and is associated with an increased risk of relapse in patients with schizophrenia, the RADAR trial has shown.